Last reviewed · How we verify
BMS-986278
BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.
BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity. Used for Acute coronary syndrome, Chronic kidney disease.
At a glance
| Generic name | BMS-986278 |
|---|---|
| Also known as | Admilparant |
| Sponsor | Bristol-Myers Squibb |
| Drug class | NLRP3 inflammasome inhibitor |
| Target | NLRP3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The NLRP3 inflammasome is a multi-protein complex that activates caspase-1, leading to the production of pro-inflammatory cytokines IL-1β and IL-18. By selectively inhibiting NLRP3, BMS-986278 dampens pathological inflammation without broadly suppressing immune function. This mechanism is relevant to inflammatory and autoinflammatory diseases where NLRP3 activation drives disease pathology.
Approved indications
- Acute coronary syndrome
- Chronic kidney disease
Common side effects
- Infection
- Elevated liver enzymes
- Gastrointestinal disorders
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis (PHASE3)
- A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (PHASE1)
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis (PHASE3)
- A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (PHASE2)
- A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis (PHASE1)
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants (PHASE1)
- A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |